Publicacións nas que colabora con Celia Miralles Álvarez (19)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

2018

  1. Real world patient-reported outcomes in HIV-infected adults switching to EVIPLERA®, because of a previous intolerance to cART. PRO-STR study

    Current HIV Research, Vol. 16, Núm. 6, pp. 425-435

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Executive summary: Prevención y tratamiento de infecciones oportunistas y otras coinfecciones en pacientes infectados por el VIH: mayo de 2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 517-523

  2. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 516.e1-516.e18

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)

    Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 7, pp. 447-458

2010

  1. El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infeccin por VIH-1

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 9, pp. 615-620

  2. Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to cd4 cell counts: Results of the TOSCANA study

    HIV Clinical Trials, Vol. 11, Núm. 1, pp. 11-17

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

  2. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2006

  1. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

    AIDS, Vol. 20, Núm. 10, pp. 1407-1414

2002

  1. Simplificación del tratamiento antirretroviral

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 20, Núm. SUPPL.2, pp. 48-57